Biomedical Mutation Analysis (BMA): A software tool for analyzing mutations associated with antiviral resistance

Area of Science:

• Virology
• Bioinformatics
• Computational Biology

Background:

• Hepatitis C virus (HCV) infection affects 200 million globally, posing a significant public health challenge.
• Current treatments for chronic HCV infection have limited efficacy (50%), necessitating novel therapeutic strategies.
• Direct-acting antivirals (DAA) show promise but face challenges due to drug-resistant mutations in HCV.

Purpose of the Study:

• To develop an online information system for identifying specific amino acid mutations in HCV.
• The system aims to detect mutations associated with resistance to direct-acting antivirals (DAA).

Main Methods:

• Utilized computational tools and algorithms to analyze resistance-associated positions in HCV NS3, NS5A, and NS5B genes.
• Developed an online system employing standard programming languages and infrastructure.
• Integrated analysis of nucleotide and amino acid sequences from Sanger and cloning sequencing data.

Main Results:

• Successfully designed and implemented the Biomedical Mutation Analysis (BMA) online system.
• BMA provides a user-friendly graphical interface for analyzing sequence mutations.
• The system facilitates the calculation of nucleotide and amino acid sequence changes.

Conclusions:

• BMA offers a quick, easy, and effective method for analyzing HCV mutations related to DAA resistance.
• Visualization tools within BMA enhance the interpretation of mutation analysis results.
• The system is valuable for assessing HCV resistance, guiding treatment regimens, and preventing treatment failures.